menu
    • menu
    [{"orgOrder":0,"company":"Eolas Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"AZD4041","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Eolas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eolas Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Eolas Therapeutics \/ AstraZeneca"}]

    Find Clinical Drug Pipeline Developments & Deals by Eolas Therapeutics

    Menu

    Eolas Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eolas Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Eolas Therapeutics

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD4041

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eolas Therapeutics Gains Full Rights to Develop AZD4041

                            Details : Eolas will assume full responsibility for the program under the existing IND application and will advance AZD4041, a highly selective orexin-1 receptor antagonist, into Phase II clinical trials.

                            Product Name : AZD4041

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 10, 2025

                            Lead Product(s) : AZD4041

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth